A force fighting HIV and hepatitis where money is scarce.
Pharmaceutical companies—especially the profitable ones—can make for easy villains in the U.S. For example, Gilead Sciences has been lambasted for the high list price of its game-changing hepatitis C cure Sovaldi, infamous as the “$1,000 pill.”
But in India, a 28-day supply of a generic version of the drug now costs just $100, according to the company. That’s because Gilead has struck deals with 11 different Indian generic drugmakers to supply affordable versions of its hep C drugs to patients in 101 developing countries. And then there’s Egypt, the nation with the highest incidence of hepatitis C in the world (more than 10% of the population is infected). Gilead slashed the price of branded Sovaldi there by 99%.
The firm takes a similar approach to its HIV franchise, which has posted strong sales in recent earnings reports. In fact, 2016 is the 10-year anniversary of Gilead’s HIV licensing agreements in the developing world, and the company says it’s on the cusp of having 10 million people in poor countries treated with its HIV drugs.
John F. Milligan
|Revenues ($M) (Last Fiscal Year)||$32,639|
|Profits ($M) (Last Fiscal Year)||$18,108|
|Market Value ($M)||$104,121|